Cambridge Epigenetix Stock

cambridge-epigenetix.comBioTechFounded: 2012Funding to Date: $57.08MM

Cambridge Epigenetix (CEGX) is a life sciences tools and analytics company that has created a technology platform delivering step changes in both the type of information that can be generated from DNA and the cost at which it is gathered.

Register for Details

For more details on financing and valuation for Cambridge Epigenetix, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Cambridge Epigenetix.

Register Today
Register for Details

For more details on financing and valuation for Cambridge Epigenetix, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Deborah Tonge
Director of Finance
Shankar Balasubramanian
Co-Founder & Chairman of Scientific Advisory Board
Joanne Mason Ph.D
Vice President, Biomarker Discovery
Vitali Proutski Ph.D
Vice President, Informatics
Jason Mellad Ph.D
Chief Executive Officer & Board Member
Hayden Jeffreys
Chief Operating Officer
Bobby Yerramilli-Rao Ph.D
Co-Founder & Chairman

Board Members

Alice Newcombe-Ellis
Ahren Innovation Capital
Bobby Yerramilli-Rao Ph.D
Jason Mellad Ph.D
Martin Murphy Ph.D
Syncona
Roelof Botha
Sequoia Capital
Shankar Balasubramanian
Somasundaram Subramaniam
New Science Ventures
Timothy Rink MD
Tom Hulme
GV

Other companies like Cambridge Epigenetix in the BioTech sector

Sector
 
 
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$185MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$1.3B
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.89B

News

VC firm GV (née Google Ventures) has made another investment in Europe -- its seventh -- leading a $21 million Series B round for epigenetic sequencing tech company and Cambridge University spin-out, Cambridge Epigenetix.